Oddity Tech (ODD) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
11 Nov, 2026Executive summary
Q3 net revenue declined 2% YoY to $145.0M, and adjusted EBITDA was $22.0M; both exceeded guidance as revenue pressure eased from H1.
FY 2026 revenue and adjusted EBITDA outlooks were raised; 2027 priorities include returning brands to growth through launches, category expansion, technology, and ODDITY Labs.
SpoiledChild and METHODIQ advanced, while resolving IL MAKIAGE’s advertising-account dislocation remains key to its planned return to growth.
Financial highlights
Q3 net revenue was $145.0M versus $147.9M a year earlier; adjusted EBITDA was $22.0M versus $28.9M, above the $18M–$20M outlook.
9M net revenue declined 20% YoY to $523.4M; adjusted EBITDA fell 82% to $27.9M.
Q3 net income was $11.2M versus $17.7M; 9M net income was $2.7M versus $104.9M.
Q3 free cash flow was $10M; 9M free cash flow was $2.5M, with operating cash flow of $4.9M and capex of $2.4M.
More than 80% of Q3 net revenue came from repeat sales; first-order net revenue declined by high teens YoY.
Outlook and guidance
FY 2026 net revenue is expected to decline 18.5%, versus prior guidance for a 19.0% decline; adjusted EBITDA guidance rose to $32M–$34M from $30M–$32M.
Q4 2026 net revenue is expected to decline 10%–11% YoY, with adjusted EBITDA of $4M–$6M.
2027 goal is to return all brands, including IL MAKIAGE, to growth; Brand Four is planned for launch, alongside product launches across existing brands.
2027 launches include ~8 SpoiledChild products and 5–6 IL MAKIAGE products; METHODIQ plans category expansion and prescription injectable and peptide therapies.
Latest events from Oddity Tech
- Q2 revenue dropped 25% year-over-year, but SpoiledChild and METHODIQ showed strong growth.ODD
Q2 2026 - Q1 2026 revenue fell 26% on high CPA, but recovery and positive EBITDA are expected.ODD
Q1 2026 - Record 2025 growth and cash flow, but Q1 2026 faces a 30% revenue drop from acquisition cost spikes.ODD
Q4 2025 - Q3 revenue and EPS grew 24%, METHODIQ launched, and full-year guidance was raised.ODD
Q3 2025 - Q2 revenue up 25%, cash at $815M, 2025 outlook raised, and Brand 3 launches in Q4.ODD
Q2 2025 - Record Q3 growth and raised 2024 outlook highlight strong D2C execution and cash flow.ODD
Q3 2024 - Record revenue growth and margin expansion drive raised 2024 outlook and strong cash position.ODD
Q2 2024 - Q1 revenue up 27% to $268M; full-year outlook raised on strong DTC and brand momentum.ODD
Q1 2025 - 27% revenue growth, strong margins, and tech-driven innovation fuel robust 2025 outlook.ODD
Q4 2024